(-)Epigallocatechin Gallate
Prod. No. E4143 – Minimum 95%
Prod. No. E4268 – Minimum 80%
Anti-oxidant that preferentially induces apoptosis in neoplastic cells
Epigallocatechin Gallate (EGCG) is an anti-oxidant polyphenol flavonoid isolated from green tea. Its possible benefit as a nutritional chemopreventive agent for cancer, atherosclerosis, and neurodegenerative diseases is generating increased scientific interest. EGCG has demonstrated chemopreventive and chemotherapeutic actions in cellular and animal models of cancer.1,2
- EGCG selectively induces apoptosis in human carcinoma cell lines.1-3
- It inhibits MAP kinase mediated signaling pathways.2,4
- EGCG blocks the activation of EGF receptors and HER-2 receptors which are over-expressed or constitutively active in many human malignancies.4,5
- It interferes with angiogenesis by suppressing VEGF activity, VE-cadherin phosphorylation and matrix metalloproteinase activity.6-8
- EGCG inhibits telomerase and DNA methyltransferase, two enzymes involved in cancer gene expression and cellular immortality.9-12
- EGCG's anti-oxidant action protects cells from lipid peroxidation and DNA damage induced by reactive free radicals.13-16
Sigma® is pleased to make this important compound available to cancer researchers.
- Borska, S., et al., Induction of apoptosis by EGCG in selected tumour cell lines in vitro. Folia Histochem. Cytobiol. 41, 229-32 (2003).
- Lambert, J.D., et al., Mechanisms of cancer prevention by tea constituents. J. Nutr. 133, 3262S-3267S (2003).
- Gupta, S. et al., Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor κB and induction of apoptosis. Oncogene 23, 2507-2522 (2004).
- Sah, J.F., et al., Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and Akt kinases. J. Biol. Chem. 279, 12755-12762 (2004).
- Masuda M, et al., Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin. Cancer Res. 9, 3486-3491 (2003).
- Tang, F.Y. et al., Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule. Int. J. Cancer 106, 871-878 (2003).
- Lee, Y.K., et al., VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG) in B cell chronic lymphocytic Leukemia. Blood. Mar 2, 2004 [Epub ahead of print]
- Tosetti, F., et al., Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J. 16, 2-14 (2002).
- Yokoyama, M. et al., The tea polyphenol, (-)-epigallocatechin gallate effects on growth, apoptosis, and telomerase activity in cervical cell lines. Gynecol Oncol. 92, 197-204 (2004).
- Didiano, D., et al.,Telomere maintenance in childhood primitive neuroectodermal brain tumors. Neuro-oncol. 6, 1-8 (2004).
- Mittal, A., et al.,EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis. Int. J. Oncol. 24, 703-710 (2004).
- Fang, M.Z., et al., Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 63, 7563-7570 (2003)
- Saffari, Y. and Sadrzadeh, S.M., Green tea metabolite EGCG protects membranes against oxidative damage in vitro. Life Sci. 74, 1513-1518 (2004).
- Peng, I.W. and Kuo, S.M., Flavonoid structure affects the inhibition of lipid peroxidation in Caco-2 intestinal cells at physiological concentrations. J. Nutr. 133, 2184-2187 (2003).
- Lee, S.R., et al., Protective effect of green tea polyphenol (-)-epigallocatechin gallate and other antioxidants on lipid peroxidation in gerbil brain homogenates. Phytother. Res. 17, 206-209 (2003)
- Sugisawa, A., et al., Anti-genotoxic effects of tea catechins against reactive oxygen species in human lymphoblastoid cells. Mutat. Res. 559, 97-103 (2004).
back to Cancer Research
back to top